Compare
Precigen, Inc. vs BioAge Labs, Inc. vs Emmaus Life Sciences, Inc. vs Tonix Pharmaceuticals Holding Corp.
| Latest fiscal year | Precigen, Inc. PGEN | BioAge Labs, Inc. BIOA | Emmaus Life Sciences, Inc. EMMA | Tonix Pharmaceuticals Holding Corp. TNXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.68M | $8.99M | $12.45M | $13.11M |
| Revenue growth (YoY) | +146.7% | n/a | -25.2% | +29.8% |
| Gross margin | n/a | n/a | 93.1% | 49.3% (computed) |
| Operating margin | n/m | n/m | 1.9% | -959.1% |
| Net margin | n/m | -896.1% | -60.2% | -946.2% |
| Net income | -$250.64M | -$80.61M | -$7.49M | -$124.02M |
| EPS (Diluted) | -$1.37 | -$2.24 | -$0.12 | -$14.57 |
| Operating cash flow | -$87.83M | -$81.63M | -$11.0K | -$99.84M |
| Free cash flow | -$89.83M | -$82.35M | -$12.0K | -$103.21M |
| Cash & equivalents | $30.23M | $188.89M | $2.13M | $207.64M |
| Total assets | $155.50M | $294.89M | $21.44M | $277.17M |
| Total liabilities | $134.59M | $22.84M | $85.04M | $32.02M |
| Shareholders' equity | $20.91M | $272.05M | -$63.61M | $245.15M |
| Return on year-end equity | n/m | -29.6% | n/a | -50.6% |
| Shares outstanding | 353.91M | 37.39M | 70.19M | 12.79M |
Revenue, most recent five fiscal years
| Fiscal year | Precigen, Inc. | BioAge Labs, Inc. | Emmaus Life Sciences, Inc. | Tonix Pharmaceuticals Holding Corp. |
|---|---|---|---|---|
| Latest | $9.68M Ended 2025-12-31 | $8.99M Ended 2025-12-31 | $12.45M Ended 2025-12-31 | $13.11M Ended 2025-12-31 |
| 1 year earlier | $3.92M Ended 2024-12-31 | $0 Ended 2024-12-31 | $16.65M Ended 2024-12-31 | $10.09M Ended 2024-12-31 |
| 2 years earlier | $6.22M Ended 2023-12-31 | n/a | $29.60M Ended 2023-12-31 | $7.77M Ended 2023-12-31 |
| 3 years earlier | $26.91M Ended 2022-12-31 | n/a | $18.39M Ended 2022-12-31 | n/a |
| 4 years earlier | $14.27M Ended 2021-12-31 | n/a | $20.61M Ended 2021-12-31 | n/a |